KIAA0101 Antibody (monoclonal) (M01)
Mouse monoclonal antibody raised against a full length recombinant KIAA0101.
|Application ||WB, IHC, IF, E|
|Calculated MW||11986 Da|
|Other Names||PCNA-associated factor, Hepatitis C virus NS5A-transactivated protein 9, HCV NS5A-transactivated protein 9, Overexpressed in anaplastic thyroid carcinoma 1, OEATC-1, PCNA-associated factor of 15 kDa, PAF15, p15PAF, KIAA0101, NS5ATP9, PAF|
|Target/Specificity||KIAA0101 (AAH05832, 1 a.a. ~ 111 a.a) full-length recombinant protein with GST tag. MW of the GST tag alone is 26 KDa.|
|Format||Clear, colorless solution in phosphate buffered saline, pH 7.2 .|
|Storage||Store at -20°C or lower. Aliquot to avoid repeated freezing and thawing.|
|Precautions||KIAA0101 Antibody (monoclonal) (M01) is for research use only and not for use in diagnostic or therapeutic procedures.|
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abgent to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
1.p15PAF Is an Rb/E2F-Regulated S-Phase Protein Essential for DNA Synthesis and Cell Cycle Progression.Chang CN, Feng MJ, Chen YL, Yuan RH, Jeng YMPLoS One. 2013 Apr 4;8(4):e61196. doi: 10.1371/journal.pone.0061196. Print 2013.2.Elevated cyclin B2 expression in invasive breast carcinoma is associated with unfavorable clinical outcome.Shubbar E, Kovacs A, Hajizadeh S, Parris TZ, Nemes S, Gunnarsdottir K, Einbeigi Z, Karlsson P, Helou K.BMC Cancer. 2013 Jan 2;13:1. doi: 10.1186/1471-2407-13-1.3.Overexpression of KIAA0101 predicts poor prognosis in primary lung cancer patients.Kato T, Daigo Y, Aragaki M, Ishikawa K, Sato M, Kaji M.Lung Cancer. 2011 Jun 18. [Epub ahead of print]4.Overexpression of KIAA0101 Predicts High Stage, Early Tumor Recurrence, and Poor Prognosis of Hepatocellular Carcinoma.Yuan RH, Jeng YM, Pan HW, Hu FC, Lai PL, Lee PH, Hsu HC.Clin Cancer Res. 2007 Sep 15;13(18):5368-76.
If you have used an Abgent product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at email@example.com.